Omontys Recall Prompts Class Action Lawsuit Investigation

Omontys Recall Prompts Class Action Lawsuit Investigation

By Sarah Pierce

On February 23, 2013, the U.S. Food and Drug Administration announced that the anemia drug Omontys had been voluntarily recalled due to reports of fatal reactions. The FDA said there had been 19 reports of anaphylaxis from U.S. dialysis centers where the drug was administered. Three of those patients died while some were able to be resuscitated by doctors, the agency said.

An estimated 25,000 patients have received intravenous injections of Omontys (peginesatide), which was approved last March for the treatment of anemia in adult dialysis patients with chronic kidney disease. Fatal reactions have been reported in approximately 0.02% of patients following their first dose of the drug. There have been no reports of such reactions following subsequent dosing, or in patients who have completed their dialysis session, the FDA said.

Overall, approximately 0.2% of Omontys users have reported hypersensitivity reactions, with approximately a third of these being serious in nature and requiring prompt medical attention or hospitalization.

If you or a loved one was administered Omontys during dialysis and experienced any of the following side effects, you may be entitled compensation through an Omontys lawsuit:

• Anaphylaxis
• Heart Attack
• Stroke
• Metabolic Alkalosis
• Low Blood Pressure
• Cardiopulmonary Arrest
• Cardiac Arrhythmia
• Rash
• Hives
• Throat or tongue swelling
• Nausea, vomiting or diarrhea

Victims of these side effects can receive a free legal review of their claims by submitting their information at the Omontys Recall Class Action Lawsuit Investigation. You may be entitled to compensation for pain and suffering, medical expenses, lost income, disability, decreased quality of life, wrongful death of your loved one, and more. Submit your information now for a free, no-obligation consultation.